By Bill Berkrot
(Reuters) – U.S. researchers on Thursday said they had found
a way to predict male sexual orientation based on molecular
markers that control DNA function, but genetics experts warned
that the research has important limitations and will not provide
definitive answers to a potential biological basis for sexual
Findings from the study, which has yet to be published or
reviewed in detail by other scientists, were presented at a
meeting of the American Society of Human Genetics in Baltimore.
NEW YORK (Reuters) – U.S. biotech shares extended their recent downward spiral on Tuesday as concerns about drug pricing continued to plague the sector while disappointing news from Illumina and other companies added to selling pressure.
The Nasdaq Biotechnology index, down 4 percent, has now fallen about 17 percent since just before Hillary Clinton, front-runner to be the Democratic nominee in next year’s U.S. presidential election, vowed on Sept. 21 to take steps to curb high drug prices.
NEW YORK/ATLANTA (Reuters) – The Pacific trade deal agreed on Monday, which grants biotechnology drug producers less protection than offered by the United States, could put more downward pressures on the costly drugs’ pricing in the industry’s most lucrative market.
The United States and 11 trading partners, including Mexico, Japan, Canada and Australia, wrapped up five years of talks after securing a compromise on protection for biotech drugs that would help determine when less expensive versions known as biosimilars can enter the market.
Oct 1 (Reuters) – The U.S. Food and Drug Administration on
Thursday approved the first combination of two drugs that help
the immune system fight cancer, a therapy regimen that could
cost $256,000 a year.
Bristol-Myers Squibb Co said the FDA had given the
green light to combine its immuno-oncology drugs Opdivo and
Yervoy to treat advanced or inoperable melanoma, the deadliest
form of skin cancer, in patients who do not have a mutation of a
gene called BRAF.
NEW YORK (Reuters) – Teva Pharmaceutical Industries Ltd’s (TEVA.TA: Quote, Profile, Research, Stock Buzz) research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the United States.
Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients’ treatment costs, just one of several ways she would prevent “profiteering” by drugmakers if elected.
By Ransdell Pierson and Bill Berkrot
(Reuters) – Democratic lawmakers on Monday attacked “massive” price increases of two heart drugs from Canada’s Valeant Pharmaceuticals International Inc, fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U.S. drug prices.
All 18 Democratic members of the House Committee on Oversight and Government Reform urged their chairman to subpoena Valeant and force it to provide documents relating to price increases of 212 percent for Isuprel and 525 percent for Nitropress. Valeant boosted the prices immediately after buying the heart drugs in February.
Sept 28 (Reuters) – Democratic lawmakers on Monday attacked
“massive” price increases of two heart drugs from Canada’s
Valeant Pharmaceuticals International Inc, fueling a rout in
drugmaker shares on worries of a government and insurer
clampdown on U.S. drug prices.
All 18 Democratic members of the House Committee on
Oversight and Government Reform urged their chairman to subpoena
Valeant and force it to provide documents relating to price
increases of 212 percent for Isuprel and 525 percent for
Nitropress. Valeant boosted the prices immediately after buying
the heart drugs in February.
BOSTON (Reuters) – Top U.S. heart doctors said on Thursday that newly developed cholesterol treatments that cost more than $14,000 per year are best used for the small group of patients for which they have been approved, at least for now.
The drugs are vastly more expensive than the statins that are currently used by tens of millions of people to help control high cholesterol and have drawn scrutiny from health insurers who are concerned they will be widely prescribed.
NEW YORK, Sept 22 (Reuters) – Hillary Clinton’s campaign
promise on Tuesday to cap prescription drug costs for U.S.
consumers lends weight to efforts by health insurers, doctors’
groups and consumers to address skyrocketing prices, industry
Clinton, in the lead among Democratic presidential
candidates, unveiled a plan that includes a $250 monthly cap on
out-of-pocket costs prescription drugs, allowing the Medicare
plan for the elderly to negotiate drug pricing and permitting
Americans to purchase drugs from other countries at lower cost.
Sept 11 (Reuters) – Lowering blood pressure below a commonly
used target significantly reduced serious heart problems and cut
the risk of death in adults aged 50 and older, according to
preliminary results of a large U.S. government-sponsored study
released on Friday.
In the study of more than 9,300 patients with hypertension,
using a combination of medicines to reduce systolic pressure to
a target of 120 versus 140 cut the rate of heart attacks,
strokes and heart failure by almost a third and the risk of
death by nearly a quarter.